Clark Estates Inc’s Catalyst Pharmaceutical CPRX Stock Holding History

Clark Estates Inc’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.82M	Hold	113,918	–	–	0.68%	22
2025 Q4	$2.66M	Hold	113,918	–	–	0.65%	26
2025 Q3	$2.24M	Hold	113,918	–	–	0.51%	46
2025 Q2	$2.47M	Sell	113,918 -20,500	-15%	-$484K	0.55%	22
2025 Q1	$3.26M	Sell	134,418 -51,325	-28%	-$1.16M	0.69%	17
2024 Q4	$3.88M	Sell	185,743 -22,507	-11%	-$484K	0.75%	20
2024 Q3	$4.14M	Sell	208,250 -16,700	-7%	-$310K	0.77%	21
2024 Q2	$3.48M	Sell	224,950 -6,050	-3%	-$94.2K	0.65%	35
2024 Q1	$3.68M	Buy	231,000 +33,500	+17%	+$505K	0.61%	41
2023 Q4	$3.32M	Buy	197,500 +9,500	+5%	+$130K	0.56%	56
2023 Q3	$2.2M	Buy	+188,000	New	+$2.51M	0.4%	79

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Clark Estates Inc's CPRX Position: Q1 2026 in Review

Clark Estates Inc held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 113,918 shares worth $2.82M. The position accounts for 0.68% of the portfolio, ranked #22.

Clark Estates Inc first reported a position in CPRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $4.14M in Q3 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Clark Estates Inc held 113,918 shares of Catalyst Pharmaceutical worth $2.82M as of Q1 2026.
Clark Estates Inc left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up 0.68% of Clark Estates Inc's portfolio in Q1 2026, its #22 holding.
Clark Estates Inc first reported a position in Catalyst Pharmaceutical in Q3 2023 and has held it in 11 quarters since.
Clark Estates Inc's Catalyst Pharmaceutical position peaked at $4.14M in Q3 2024.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Clark Estates Inc's 13F filing for Q1 2026, filed 11 May 2026.